<DOC>
	<DOCNO>NCT02064348</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate effect semaglutide cardiac repolarisation healthy subject .</brief_summary>
	<brief_title>A Thorough QTc Evaluation Effect Semaglutide Cardiac Repolarisation Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>BMI ( Body Mass Index ) : 2030 kg/m^2 Body weight : 60110 kg Normal ECG ( electrocardiogram ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method . Women childbearing potential must use effective method birth control duration trial 5 week follow last dose semaglutide . Only highly effective method birth control accept ( i.e . one result less 1 % per year failure rate use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ) , sexual abstinence vasectomise partner Any clinically significant disease history , opinion investigator , systemic organ History seizure , epilepsy , syncope , cardiac arrest , cardiac arrhythmia Torsades de Pointes , AV ( Atrioventricular ) block structural heart disease Family history long QT ( Interval ECG : start QRS complex end ) syndrome ( either objectively diagnose suggest sudden death due cardiac cause age 50 1st degree relative ) Family history sudden cardiac death age 50 1st degree relative Use prescription nonprescription systemic topical medicinal product ( except routine vitamin , acetylsalicylic acid , paracetamol contraceptive ) within 3 week ( within 5 halflives medicinal product , whichever long ) prior first dose semaglutide Smoking , drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>